These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 17729237

  • 1. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
    Delgado-Enciso I, Cervantes-García D, Martínez-Dávila IA, Ortiz-López R, Alemany-Bonastre R, Silva-Platas CI, Lugo-Trampe A, Barrera-Saldaña HA, Galván-Salazar HR, Coronel-Tene CG, Sánchez-Santillán CF, Rojas-Martínez A.
    J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
    [Abstract] [Full Text] [Related]

  • 2. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter.
    Nettelbeck DM, Rivera AA, Balagué C, Alemany R, Curiel DT.
    Cancer Res; 2002 Aug 15; 62(16):4663-70. PubMed ID: 12183423
    [Abstract] [Full Text] [Related]

  • 3. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B, Liu X, Fan J, Qi R, Bo L, Gu J, Qian Q, Qian C, Liu X.
    J Gene Med; 2006 Oct 15; 8(10):1232-42. PubMed ID: 16900558
    [Abstract] [Full Text] [Related]

  • 4. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, Huang Y, Kaloss M, Marinov A, Phipps S, Pinkstaff A, Shirley P, Skripchenko Y, Stewart D, Forry-Schaudies S, Hallenbeck PL.
    Cancer Res; 2003 Apr 01; 63(7):1490-9. PubMed ID: 12670895
    [Abstract] [Full Text] [Related]

  • 5. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H, Zhang L, Tang Y, Deisseroth A.
    Cancer Gene Ther; 2003 May 01; 10(5):388-95. PubMed ID: 12719708
    [Abstract] [Full Text] [Related]

  • 6. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB, Wu CT, Wang H, Zhang QW, Wang L, Wang RL, Lu ZZ, Wang LS.
    Cancer Gene Ther; 2008 Mar 01; 15(3):173-82. PubMed ID: 18157145
    [Abstract] [Full Text] [Related]

  • 7. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
    Ye X, Lu Q, Zhao Y, Ren Z, Ren XW, Qiu QH, Tong Y, Liang M, Hu F, Chen HZ.
    Int J Mol Med; 2005 Dec 01; 16(6):1179-84. PubMed ID: 16273304
    [Abstract] [Full Text] [Related]

  • 8. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q, Chen G, Peng L, Wang X, Yang Y, Liu C, Shi W, Su C, Wu H, Liu X, Wu M, Qian Q.
    Clin Cancer Res; 2006 Nov 01; 12(21):6523-31. PubMed ID: 17085667
    [Abstract] [Full Text] [Related]

  • 9. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, Cardoza L, Lebkowski JS, Majumdar AS.
    Cancer Gene Ther; 2004 Mar 01; 11(3):174-85. PubMed ID: 14726958
    [Abstract] [Full Text] [Related]

  • 10. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16.
    Griffith C, Noonan S, Lou E, Shillitoe EJ.
    Cancer Gene Ther; 2007 Dec 01; 14(12):985-93. PubMed ID: 17853922
    [Abstract] [Full Text] [Related]

  • 11. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
    Lam JT, Kanerva A, Bauerschmitz GJ, Takayama K, Suzuki K, Yamamoto M, Bhoola SM, Liu B, Wang M, Barnes MN, Alvarez RD, Siegal GP, Curiel DT, Hemminki A.
    J Gene Med; 2004 Dec 01; 6(12):1333-42. PubMed ID: 15493039
    [Abstract] [Full Text] [Related]

  • 12. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer--expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy.
    Kanai R, Eguchi K, Takahashi M, Goldman S, Okano H, Kawase T, Yazaki T.
    J Gene Med; 2006 Nov 01; 8(11):1329-40. PubMed ID: 16955534
    [Abstract] [Full Text] [Related]

  • 13. Oncolytic adenovirus armed with human papillomavirus E2 gene in combination with radiation demonstrates synergistic enhancements of antitumor efficacy.
    Wang W, Xia X, Wang S, Sima N, Li Y, Han Z, Gao Q, Luo A, Li K, Meng L, Zhou J, Wang C, Shen K, Ma D.
    Cancer Gene Ther; 2011 Nov 01; 18(11):825-36. PubMed ID: 21852812
    [Abstract] [Full Text] [Related]

  • 14. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
    Bauerschmitz GJ, Guse K, Kanerva A, Menzel A, Herrmann I, Desmond RA, Yamamoto M, Nettelbeck DM, Hakkarainen T, Dall P, Curiel DT, Hemminki A.
    Mol Ther; 2006 Aug 01; 14(2):164-74. PubMed ID: 16580264
    [Abstract] [Full Text] [Related]

  • 15. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X, Jung C, Liu YH, Bae KH, Zhang YP, Zhang HJ, Vanderputten D, Jeng MH, Gardner TA, Kao C.
    J Gene Med; 2006 Jun 01; 8(6):679-89. PubMed ID: 16570242
    [Abstract] [Full Text] [Related]

  • 16. Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer.
    Heideman DA, Steenbergen RD, van der Torre J, Scheffner M, Alemany R, Gerritsen WR, Meijer CJ, Snijders PJ, van Beusechem VW.
    Mol Ther; 2005 Dec 01; 12(6):1083-90. PubMed ID: 16085463
    [Abstract] [Full Text] [Related]

  • 17. Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacy.
    Su C, Na M, Chen J, Wang X, Liu Y, Wang W, Zhang Q, Li L, Long J, Liu X, Wu M, Fan X, Qian Q.
    Mol Cancer Res; 2008 Apr 01; 6(4):568-75. PubMed ID: 18344493
    [Abstract] [Full Text] [Related]

  • 18. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis.
    Lanson NA, Friedlander PL, Schwarzenberger P, Kolls JK, Wang G.
    Cancer Res; 2003 Nov 15; 63(22):7936-41. PubMed ID: 14633724
    [Abstract] [Full Text] [Related]

  • 19. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
    Fuerer C, Homicsko K, Lukashev AN, Pittet AL, Iggo RD.
    BMC Cancer; 2006 Oct 04; 6():236. PubMed ID: 17020613
    [Abstract] [Full Text] [Related]

  • 20. Tumor-specific therapeutic effect induced by an oncolytic adenoviral vector containing heat shock protein 70 and prodrug activation genes.
    Liu Y, Ye T, Sun D, Maynard J, Deisseroth A.
    Gene Ther; 2006 Aug 04; 13(16):1235-43. PubMed ID: 16617300
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.